Tumor-infiltrating Lymphocytes in Melanoma

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2012 Aug 11

PMID 22878966

Citations 50

Authors

Sylvia Lee

Kim Margolin

Affiliations

Soon will be listed here.

Abstract

Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective treatment for patients with metastatic melanoma. With higher response rates than ipilimumab or IL-2, and longer durations of response than vemurafenib, TIL therapy carries the potential to transform current outcomes in melanoma, while also defining the way cell-based immunotherapy gets incorporated into mainstream cancer treatment. This paper will review the current state of TIL therapy in melanoma, the strategies to improve its efficacy, the current obstacles, and future directions to expand the availability of TIL to the general patient population.

Citing Articles

Exosome-based immunotherapy as an innovative therapeutic approach in melanoma.

Babaei S, Fadaee M, Abbasi-Kenarsari H, Shanehbandi D, Kazemi T Cell Commun Signal. 2024; 22(1):527.

PMID: 39482766 PMC: 11526674. DOI: 10.1186/s12964-024-01906-1.

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.

Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler M, Haanen J J Immunother Cancer. 2024; 12(2).

PMID: 38423748 PMC: 11005706. DOI: 10.1136/jitc-2023-008735.

The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.

Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y Br J Cancer. 2023; 129(7):1041-1049.

PMID: 37452117 PMC: 10539364. DOI: 10.1038/s41416-023-02321-y.

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.

Mulgaonkar A, Udayakumar D, Yang Y, Harris S, Oz O, Ramakrishnan Geethakumari P Front Med (Lausanne). 2023; 10:1199146.

PMID: 37441689 PMC: 10333708. DOI: 10.3389/fmed.2023.1199146.

Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial.

Bujak J, Klek S, Balawejder M, Kociniak A, Wilkus K, Szatanek R JMIR Res Protoc. 2023; 12:e45872.

PMID: 37440307 PMC: 10375398. DOI: 10.2196/45872.

References

Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C . White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011; 17(7):1664-73. DOI: 10.1158/1078-0432.CCR-10-2272. View

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

Robbins P, Dudley M, Wunderlich J, El-Gamil M, Li Y, Zhou J . Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004; 173(12):7125-30. PMC: 2175171. DOI: 10.4049/jimmunol.173.12.7125. View

Goff S, Smith F, Klapper J, Sherry R, Wunderlich J, Steinberg S . Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010; 33(8):840-7. PMC: 6322671. DOI: 10.1097/CJI.0b013e3181f05b91. View

Hinrichs C, Borman Z, Gattinoni L, Yu Z, Burns W, Huang J . Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2010; 117(3):808-14. PMC: 3035075. DOI: 10.1182/blood-2010-05-286286. View

Fefer A . Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 1969; 29(12):2177-83. View

Rosenberg S, Sportes C, Ahmadzadeh M, Fry T, Ngo L, Schwarz S . IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006; 29(3):313-9. PMC: 1473976. DOI: 10.1097/01.cji.0000210386.55951.c2. View

Boni A, Cogdill A, Dang P, Udayakumar D, Jenny Njauw C, Sloss C . Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70(13):5213-9. DOI: 10.1158/0008-5472.CAN-10-0118. View

Donia M, Junker N, Ellebaek E, Andersen M, Straten P, Svane I . Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand J Immunol. 2011; 75(2):157-67. DOI: 10.1111/j.1365-3083.2011.02640.x. View

10.

Muller A, Scherle P . Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006; 6(8):613-25. DOI: 10.1038/nrc1929. View

11.

Rosenberg S, Yang J, Sherry R, Kammula U, Hughes M, Phan G . Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17(13):4550-7. PMC: 3131487. DOI: 10.1158/1078-0432.CCR-11-0116. View

12.

Mitchison N . Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955; 102(2):157-77. PMC: 2136501. DOI: 10.1084/jem.102.2.157. View

13.

Antony P, Piccirillo C, Akpinarli A, Finkelstein S, Speiss P, Surman D . CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005; 174(5):2591-601. PMC: 1403291. DOI: 10.4049/jimmunol.174.5.2591. View

14.

Koya R, Mok S, Otte N, Blacketor K, Comin-Anduix B, Tumeh P . BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72(16):3928-37. PMC: 3422880. DOI: 10.1158/0008-5472.CAN-11-2837. View

15.

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

16.

Wilmott J, Long G, Howle J, Haydu L, Sharma R, Thompson J . Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2011; 18(5):1386-94. DOI: 10.1158/1078-0432.CCR-11-2479. View

17.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

18.

Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S . Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313(23):1485-92. DOI: 10.1056/NEJM198512053132327. View

19.

Cheever M, Kempf R, Fefer A . Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol. 1977; 119(2):714-8. View

20.

Eberlein T, Rosenstein M, Rosenberg S . Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982; 156(2):385-97. PMC: 2186754. DOI: 10.1084/jem.156.2.385. View